Unique ID issued by UMIN | UMIN000011394 |
---|---|
Receipt number | R000012492 |
Scientific Title | Practical evaluation of SCr and uric acid variation for hepatitis C virus infection using a telaprevir |
Date of disclosure of the study information | 2013/09/01 |
Last modified on | 2016/02/06 11:11:21 |
Practical evaluation of SCr and uric acid variation for hepatitis C virus infection using a telaprevir
Practical evaluation of SCr and uric acid variation for hepatitis C virus infection using a telaprevir
Practical evaluation of SCr and uric acid variation for hepatitis C virus infection using a telaprevir
Practical evaluation of SCr and uric acid variation for hepatitis C virus infection using a telaprevir
Japan |
chronic hepatitis C infection
Hepato-biliary-pancreatic medicine | Adult |
Others
NO
To evaluate the variation of serum creatinine and uric acid for hepatitis C infection using telaprevir
Safety
case-control study
Observational
Not applicable |
Not applicable |
Male and Female
All patients of hepatitis C infection who treat telaprevir/peginterferon/ribavirin
none
20
1st name | |
Middle name | |
Last name | Katsuomi Matsui |
St. Marianna University School of Medicine, Kanagawa, Japan
Department of Nephrology and Hypertension, Internal Medicine
2-16-1 Sugao, Miyamae-Ku, Kawasaki 216-8511, Japan
0449778111
m.katsuomi@marianna-u.ac.jp
1st name | |
Middle name | |
Last name | Katsuomi matsui |
St. Marianna University School of Medicine, Kanagawa, Japan
Department of Nephrology and Hypertension, Internal Medicine
2-16-1 Sugao, Miyamae-Ku, Kawasaki 216-8511, Japan
0449778111
m.katsuomi@marianna-u.ac.jp
St. Marianna University School of Medicine, Kanagawa, Japan
none
Other
NO
聖マリアンナ医科大学病院(神奈川県)
2013 | Year | 09 | Month | 01 | Day |
Published
Although there was no difference in SCr level between the two groups before HCV therapy, the SCr level was persistently high in the patients in the increase-in-SCr group during the triple therapy. The SCr level returned to the pre-treatment level after cessation of TVR. There were no differences in urinary L-FABP, NAG, serum cystatin C level and eGFRcys throughout the study between the two groups. The serum cystatin C level at pre-treatment tended to be higher in the increase-in-SCr group. Urinary L-FABP and NAG levels in these groups remained within normal limits during treatment. We found that the increase in SCr was not associated with the degree of renal impairment. The increase in SCr may have been induced as a result of a decrease in creatinine secretion from proximal tubules via inhibition of transporters of creatinine induced by TVR.
Conclusion: Elevation of SCr levels with TVR therapy may not suggest renal impairment.
Completed
2012 | Year | 03 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
2014 | Year | 12 | Month | 31 | Day |
2014 | Year | 12 | Month | 31 | Day |
2016 | Year | 02 | Month | 06 | Day |
case-control study
2013 | Year | 08 | Month | 06 | Day |
2016 | Year | 02 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012492
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |